Samsung Epise Holdings announced on May 29 that it will establish a research and development (R&D) center in China to strengthen its drug development capabilities.
The company has recently founded a wholly-owned subsidiary, Samsung Biologics China Co., Ltd., in the Changping District of Beijing, aimed at biopharmaceutical research and development.
Samsung Epise Holdings, which launched as a bio-investment holding company in November 2022, has been pursuing various business strategies to enhance its future ventures. The establishment of this global R&D hub is part of its efforts to secure next-generation technology platforms, such as antibody-drug conjugates (ADCs), and to bolster its drug development capabilities.
Changping District is recognized for its rich research and development infrastructure and human resources, being home to the Zhongguancun Life Science Park and in proximity to major universities like Peking University and Tsinghua University. The center is set to officially open in June and will operate with locally hired staff.
Meanwhile, Samsung Bioepis plans to continue its drug development efforts through open innovation. In March, it initiated the global Phase 1 clinical trial for its first ADC candidate, SBE303. The second candidate, SBE313, which is being developed in collaboration with Frontline in China, is currently in the preclinical stage.
Kim Kyung-ah, CEO of Samsung Epise Holdings, stated, "The establishment of the China R&D center is part of our strategy to enhance global research and development capabilities. We will leverage local talent and technological infrastructure to improve our next-generation biopharmaceutical development capabilities."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.